SPONSOR
Sichuan University
Total Trials
3
Recruiting
3
Phases
EARLY_Phase 1, Phase 1, Phase 2
Conditions studied: NeuroblastomaPancreatic CancerAdjuvant TherapyLung CancerNon-small Cell Lung Cancer
Sichuan University is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Neuroblastoma, Pancreatic Cancer, Adjuvant Therapy, Lung Cancer.
The trial portfolio spans EARLY_Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sichuan University
How many clinical trials has Sichuan University sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Sichuan University, of which 3 are actively recruiting participants. These trials cover conditions including Neuroblastoma, Pancreatic Cancer, Adjuvant Therapy. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sichuan University research focus on?
Sichuan University clinical trials span Neuroblastoma, Pancreatic Cancer, Adjuvant Therapy, Lung Cancer, Non-small Cell Lung Cancer. The research pipeline includes EARLY_Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sichuan University clinical trial?
To participate in a Sichuan University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sichuan University trials with current recruitment status updated daily.
Clinical Trials by Sichuan University
NCT07067346 EARLY_Phase 1
Recruiting
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
Neuroblastoma
NCT06344156 Phase 1
Recruiting
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Pancreatic Cancer
NCT06877299 Phase 2
Recruiting
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology